Skip navigation
Please use this identifier to cite or link to this item: https://repositorio.unb.br/handle/10482/40462
Files in This Item:
File Description SizeFormat 
ARTIGO_CompreensiveSystematicReview.pdf1,79 MBAdobe PDFView/Open
Title: A comprehensive systematic review of leishmaniasis in patients undergoing drug-induced immunosuppression for the treatment of dermatological, rheumatological and gastroenterological diseases
Authors: Kurizky, Patricia Shu
Marianelli, Fernanda Ferraço
Cesetti, Mariana Vicente
Damiani, Giovanni
Sampaio, Raimunda Nonata Ribeiro
Gonçalves, Lais Mitsue Tanaka
Sousa, Carlos Augusto Felipe de
Martins, Sofia Sales
Vernal, Sebastian
Mota, Licia Maria Henrique da
Gomes, Ciro Martins
metadata.dc.identifier.orcid: http://orcid.org/0000-0002-3069-6884
Assunto:: Imunossupressão
Leishmaniose
Revisão sistemática
Tratamento
Issue Date: 2020
Publisher: Instituto de Medicina Tropical
Citation: KURIZKY, Patrícia Shu et al. A comprehensive systematic review of leishmaniasis in patients undergoing drug-induced immunosuppression for the treatment of dermatological, rheumatological and gastroenterological diseases. Revista do Instituto de Medicina Tropical de São Paulo, São Paulo, v. 62, e28, 2020. DOI: https://doi.org/10.1590/s1678-9946202062028. Disponível em: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46652020000100217&lng=en&nrm=iso. Acesso em: 05 abr. 2021.
Abstract: Immunosuppression is an important risk factor for leishmaniasis. We assessed the clinical profile, geographic distribution and prevalence of leishmaniasis in patients undergoing immunosuppressive therapy for dermatological, rheumatological or gastroenterological autoimmune diseases. We identified relevant studies in PubMed, EMBASE, Scopus, Web of Science and LILACS on July 3rd, 2018. We included articles that reported at least one case of leishmaniasis in patients undergoing immunosuppressive treatment for dermatological, rheumatological or gastroenterological diseases. Our protocol was registered in PROSPERO (CRD42018103050). We assessed the quality of the included studies with the Joanna Briggs Institute Critical Appraisal Tool. After the removal of duplicates, 5,431 articles were collected and screened. We included 138 articles; the prevalence of leishmaniasis in six methodologically similar studies varied from three to 1,282 cases per 100,000 patients using anti-TNFα drugs, but the results were significantly heterogeneous . Leishmaniasis in patients treated with immunosuppressive drugs is a health problem mostly reported in European countries bordering the Mediterranean Sea; sporadic activities, such as travelling, seem not to be associated with a significant risk of leishmaniasis, although effective control measures must always be observed.
Licença:: (CC BY NC) - This is an open-access article distributed under the terms of the Creative Commons Attribution License.
DOI: https://doi.org/10.1590/s1678-9946202062028
Appears in Collections:FMD - Artigos publicados em periódicos e preprints
PPGCS - Artigos publicados em periódicos e preprints

Show full item record Recommend this item " class="statisticsLink btn btn-primary" href="/handle/10482/40462/statistics">



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.